Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis

Autor: Sherban, A. ^*, Raanani, P., Gurion, R., Wolach, O., Gafter-Gvili, A.

Publikováno v: In Leukemia Research February 2022 113

Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

Autor: Schuster, M. Zijlstra, J. Casasnovas, R.-O. Vermaat, J.S.P. Kalakonda, N. Goy, A. Choquet, S. Neste, E.V.D. Hill, B. Thieblemont, C. Cavallo, F. De la Cruz, F. Kuruvilla, J. Hamad, N. Jaeger, U. Caimi, P. Gurion, R. Warzocha, K. Bakhshi, S. Sancho, J.-M. Follows, G. Egyed, M. Offner, F. Vassilakopoulos, T. Samal, P. Ku, M. Ma, X. Corona, K. Chamoun, K. Shah, J. Shacham, S. Kauffman, M.G. Canales, M. Maerevoet, M.

Background: Despite a number of treatment options, patients with diffuse large B-cell lymphoma (DLBCL) whose disease has become refractory to treatment have a poor prognosis. Selinexor is a novel, oral drug that is approved to treat patients with rel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::c68321e34dc803adc3440696e2f723b6
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076911

GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.

Autor: Hutchings, M., Avigdor, A., Sureda, A., Terol, M. J., Bosch, F., Corradini, P., Larsen, T. Stauffer, Domínguez, A. Rueda, Skarbnik, A., Jørgensen, J., Goldschmidt, N., Gurion, R., Zinzani, P. L., Pinto, A., Cordoba, R., Bottos, A., Huang, Z., Simko, S., Relf, J., Filézac de L'Etang, A.

Publikováno v: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p138-140, 3p

Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Autor: Shah, J. Shacham, S. Kauffman, M. Daniele, P. Tomaras, D. Tremblay, G. Casasnovas, R.-O. Maerevoet, M. Zijlstra, J. Follows, G. P Vermaat, J.S. Kalakonda, N. Goy, A.H. Choquet, S. Den Neste, E.V. Hill, B.T. Thieblemont, C. Cavallo, F. La Cruz, F.D. Kuruvilla, J. Hamad, N. Bouabdallah, R. Jäger, U. Caimi, P. Gurion, R. Warzocha, K. Bakhshi, S. Sancho, J.M. Schuster, M. Egyed, M. Offner, F. Vasilakopoulos, T.P. Samal, P. Nagy, A. Ku, M. Canales Albendea, M.Á.

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::0e2f811591694d3135f36e92cda83222
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077132

Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open -label, phase 2 trial

Autor: Kalakonda, N., Maerevoet, M., Cavallo, F., Follows, G., Goy, A., Vermaat, J.S.P., Casasnovas, O., Hamad, N., Zijlstra, J.M., Bakhshi, S., Bouabdallah, R., Choquet, S., Gurion, R., Hill, B., Jaeger, U., Sancho, J.M., Schuster, M., Thieblemont, C., Cruz, F. de la, Egyed, M., Mishra, S., Offner, F., Vassilakopoulos, T.P., Warzocha, K., McCarthy, D., Ma, X.W., Corona, K., Saint-Martin, J.R., Chang, H., Landesman, Y., Joshi, A., Wang, H.W., Shah, J., Shacham, S., Kauffman, M., Neste, E. van den, Canales, M.A.

Publikováno v: Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Lancet Haematology, 7(7), E509-E522. ELSEVIER SCI LTD

Background Relapsed or refractory diffuse large B -cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months. We aimed to assess the response to single -agent selinexor, an oral selective inhibitor of nuclear

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0b56206d52c8c303f1c0c046e72501ef
https://hdl.handle.net/1887/3185058